Verdiva Bio
PrivateLast Round
Series A
Jan 9, 2025
Total Funding Raised
$411M
Company Overview
Verdiva Bio operates in Healthcare & Life Sciences and is based in Guildford. Its latest recorded funding round was a Series A round in January 2025.
Verdiva Bio is a biopharmaceutical company that develops next-generation oral and injectable therapies for obesity, cardiometabolic disorders, and related complications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Verdiva Bio Comparables
Compare Verdiva Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pfizer | 85% | |
| Alveus Therapeutics | 82% | |
| Kailera Therapeutics | 81% |
For institutional investors. Book with your work email.
Verdiva Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Verdiva Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| RA Capital Management | Series A |
| Forbion | Series A |
| LYFE Capital | Series A |
| OrbiMed | Series A |
| Logos Capital | Series A |
| Lilly Asia Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 24, 2026
Grew 17% QoQ, from 64 to 75 employees.
- Apr 25, 2026
Grew 25% QoQ, from 59 to 74 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 29, 2026
Verdiva Bio Limited presents preclinical data on VRB-103 at the European Association for the Study of Diabetes (EASD) Annual Meeting in Italy from Sep 28th-Oct 2nd '26.
For institutional investors. Book with your work email.
Verdiva Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Verdiva Bio's valuation, stock price, and market status.
Is Verdiva Bio a public or private company?
Verdiva Bio is a private company.
What is the current stock price of Verdiva Bio?
Verdiva Bio is a private company, so its shares have no public market price. Caplight tracks Verdiva Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Verdiva Bio worth (valuation)?
Valuation information for Verdiva Bio is not publicly available.
Can I buy Verdiva Bio stock?
Verdiva Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Verdiva Bio's last funding round?
Verdiva Bio's most recent funding round was Series A on January 9, 2025.
Who are the main investors in Verdiva Bio?
Key investors in Verdiva Bio include Forbion Capital Partners, Forbion, General Atlantic.
Will Verdiva Bio IPO soon?
No public IPO plans have been announced for Verdiva Bio.
How can I track Verdiva Bio secondary market activity?
Caplight tracks bids, offers, and trades in Verdiva Bio's shares on secondary markets.